PPARA and metabolic dysfunction-associated steatotic liver disease: Moreover, in vitro analyses revealed that the main metabolite of Sweroside in the rats’ body, Sweroside aglycone (Sweroside-M1), could activate PPAR-α transcription, offering an additional avenue for its therapeutic effects on NAFLD.